Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Thrombosis: early-phase trial registry
7 of 30 indexed Thrombosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #519 of 28,707 conditions by registered trial count.
30 US clinical trials · 7 currently recruiting · #519 of 28,707 conditions by registered trial count
Thrombosis: 30 US clinical trials tracked, 7 recruiting.
Thrombosis is the subject of 30 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is Bristol-Myers Squibb, running 4 of these trials.
Enrollment posture brief
Registry condition thrombosis
OPEN 7 | RECR 23% | LATE 5 | EARLY 12 | RANK #519 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Alzheimers Disease (23% recruiting · 150 trials)
Thrombosis lists 7 open slots (23% of 30 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Thrombosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Thrombosis is recruiting below its size-band peers.
7 of 30 indexed trials (23.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Thrombosis trials is spread across many organizations.
Bristol-Myers Squibb accounts for 4 of 30 trials (13.3%). 24 distinct sponsors appear on at least one study for this condition label.
-
Typical Thrombosis enrolment sits around 50 participants.
Median target enrolment is 50 among the 29 trials that report a genuine target (sentinel values excluded). 16 of those (55.2%) plan for fewer than 100 participants.
-
Thrombosis splits between interventional and observational designs.
20 interventional and 10 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
30 total, page 1 of 1
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
American Thrombosis and Hemostasis Network
NCT04398628
Neonatal Platelet Transfusion Threshold Trial
NICHD Neonatal Research Network
NCT06676904
Vascular Lab Resource (VLR) Biorepository
The Cleveland Clinic
NCT05628948
Pharmacogenomics of Warfarin in Hispanics and Latinos
University of Arizona
NCT02972385
Platelet Volunteers, Longitudinal and Multi-omic Study
National Heart, Lung, and Blood Institute (NHLBI)
NCT07137429
Positron Emission Tomography (PET) Imaging of Thrombosis
Massachusetts General Hospital
NCT03830320
Extracellular Vesicle Micro RNA Profiling in Congenital Heart Disease: Fetal-Maternal Regulation in Neonatal Thrombosis
Boston Children's Hospital
NCT06434207
Diffusion of Use of Low Molecular Weight Heparin for Thrombosis on the Medicine Services
University of Chicago
NCT00203970
Antithrombotic Activities of Sotagliflozin vs. Empagliflozin
Icahn School of Medicine at Mount Sinai
NCT06618976
The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings
Medco Health Solutions
NCT00830570
Risk of Central Venous Stenosis in Patients With Chronic Renal Failure After IJ Line Placement
University of Chicago
NCT01988766
Risk of Developing Antibodies to Heparin-PF4 After Heart Surgery
Duke University
NCT00237328
A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
Daiichi Sankyo
NCT00398216
Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery
University of Utah
NCT04305756
Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion
ARCA Biopharma
NCT00073554
Prevalence of MTHFR Polymorphisms in Venous Disease
Health Diagnostic Laboratory
NCT01993914
Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)
The Medicines Company
NCT00043940
Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome
Scott C. Woller, MD
NCT02295475
Study Of Angiomax In Infants Under Six Months With Thrombosis
The Medicines Company
NCT00043277
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
Encysive Pharmaceuticals
NCT00039858
Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment
Bristol-Myers Squibb
NCT03196206
Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects
Aronora
NCT03453060
Sildenafil To Prevent Clot
Montefiore Medical Center
NCT03199612
Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers
Pfizer
NCT00914641
Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"
Bristol-Myers Squibb
NCT02671461
PFA-100 Responsive to Effect of Energy Drinks on Platelet Function
St. Louis University
NCT02997111
Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra
Thomas Jefferson University
NCT02270918
Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants
Bristol-Myers Squibb
NCT03939702
A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment
Bristol-Myers Squibb
NCT02902679
Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters
ARCA Biopharma
NCT00322270
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 4 |
| Phase 3 | 2 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Thrombosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Thrombosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Thrombosis page
30 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Thrombosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Bristol-Myers Squibb sponsors the most Thrombosis trials on record, review their full trial history before evaluating a specific study. See Bristol-Myers Squibb's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Thrombosis condition card totals 30 registered trials; most-linked intervention BMS-986177; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.